Skip to main content

16-02-2017 | Image

Table 3: Clinical efficacy of immune-checkpoint inhibitors

*Comprises DLBCL, follicular lymphoma, primary mediastinal B-cell lymphoma, and other B-cell lymphomas; data from this study for patients with DLBCL and follicular lymphoma are shown separately in the following two rows. In reported abstract. §In published report. Abbreviations: BMS, Bristol-Myers Squibb; B-NHL, B-cell non-Hodgkin lymphoma; CR, complete response; DLBCL, diffuse large-B-cell lymphoma; NR, not applicable or available; ORR, overall response rate; PR, partial response; SD, stable disease; T-NHL, T-cell non-Hodgkin lymphoma.

Image Credits